COSCIENS Biopharma

Industry

  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing

Other Names/Subsidiaries

  • Aeterna Zentaris
  • Ceapro
  • Ceapro
  • Zentaris
See more in Biomedtracker

Latest on COSCIENS Biopharma

Scrip

Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Will Market Lilly’s Emgality, R

Scrip

Veru Hopes To Position Enobosarm As Muscle-Protective In Weight-Loss Therapy

 
• By Joseph Haas

Veru Inc. started out focused mainly on cancer supportive therapy, but now thinks it has identified a new direction for its lead candidate, the selective androgen receptor modulator (SARM) enobosarm,

Scrip

Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes

 
• By Joseph Haas and Mandy Jackson

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. New Vertex/CRISPR Pact Centers On Gene-

Scrip

Tech Transfer Roundup: BridgeBio’s R&D Efforts Span New Seven New Agreements

 
• By Joseph Haas

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl